Birevim

Birevim is primarily a Turkish savings finance company that has selectively participated in the venture ecosystem through corporate venture-style cheques in the $250k-$1M range at Seed and Series A, with exposure to fintech and consumer technologies including digital health platforms whose distribution intersects with Birevim’s customer base. For founders, Birevim is best understood as a strategic CVC anchored in financial services rather than a healthcare-thesis investor, useful for digital health platforms with a clear consumer finance, savings, or insurance distribution angle in Turkey. The right founder profile is a Turkish operator building a digital health platform with embedded finance, insurance distribution, or consumer payment integration where Birevim’s customer base or operational rails create real synergy. Founders running deep biotech, hospital networks, AI clinical software without consumer finance angle, or pure B2B enterprise health software are a poor fit. Entry path is via Birevim’s strategy team, warm introductions from Istanbul-based VCs (Bogazici, ACT, 500 Istanbul), or referrals from existing portfolio companies. In the pitch, lead with concrete partnership economics with Birevim proper, distribution roadmap, regulatory navigation through BDDK, SPK, and TITCK where relevant, and a clear post-investment Series A plan. Caveats: as a corporate finance company rather than a dedicated venture fund, Birevim’s deal cadence is uneven and AI focus is not a stated priority, so AI-heavy founders should expect commercial rather than technical diligence. Term sheets may include strategic terms tied to Birevim’s distribution and customer engagement that founders should review carefully. Public deal footprint in healthcare specifically is thin, so request a recent deal sheet during initial diligence to confirm pacing and verify whether digital health remains a live theme for the current vintage. Treat as opportunistic CVC rather than primary lead.